{
  "primary": "TDP-43",
  "interaction_type": "direct",
  "upstream_interactor": null,
  "mediator_chain": [],
  "depth": 1,
  "support_summary": "VCP functions as a protein segregase that directly recognizes and extracts aggregated TDP-43 (TAR DNA-binding protein 43) from cellular inclusions for subsequent degradation, a process disrupted in VCP-related diseases.",
  "functions": [
    {
      "function": "TDP-43 Aggregate Clearance",
      "arrow": "activates",
      "cellular_process": "VCP, a type II AAA+ ATPase, functions as a protein segregase that recognizes and extracts ubiquitinated TDP-43 from insoluble aggregates in both the nucleus and cytoplasm. This process is dependent on VCP's ATPase activity, which provides the energy to unfold and solubilize TDP-43, thereby facilitating its subsequent degradation through pathways like the proteasome or autophagy. This function is critical for maintaining protein homeostasis (proteostasis) and mitigating the neurotoxicity associated with TDP-43 proteinopathies.",
      "effect_description": "VCP directly facilitates the disassembly and clearance of toxic TDP-43 aggregates. Impairment of VCP function, through mutation or inhibition, leads to the accumulation of these aggregates, a key pathological hallmark in diseases like ALS and FTD.",
      "biological_consequence": [
        "Pathological TDP-43 aggregates form in the nucleus or cytoplasm → Aggregates become ubiquitinated → The VCP hexameric complex recognizes and binds to ubiquitinated TDP-43 → VCP's D2 domain ATPase activity drives the unfolding and extraction of TDP-43 monomers from the aggregate → Solubilized TDP-43 is targeted for degradation → Cellular proteotoxicity is reduced and neuronal function is preserved."
      ],
      "specific_effects": [
        "Disease-causing mutations in VCP are associated with reduced clearance of intranuclear and cytoplasmic TDP-43 aggregates.",
        "Pharmacological activation of VCP's D2 ATPase activity enhances the clearance of insoluble intranuclear TDP-43 aggregates.",
        "VCP colocalizes with ubiquitinated TDP-43 inclusions in affected tissues of patients with TDP-43 proteinopathies."
      ],
      "evidence": [
        {
          "paper_title": "VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models",
          "journal": "The Journal of Clinical Investigation",
          "year": 2024,
          "relevant_quote": "Consistent with a loss of nuclear VCP function, cells harboring MSP variants or cells treated with VCP inhibitor exhibited decreased clearance of insoluble intranuclear TDP-43 aggregates. Moreover, we identified 4 compounds that activate VCP primarily by increasing D2 ATPase activity, where pharmacologic VCP activation appears to enhance clearance of insoluble intranuclear TDP-43 aggregate.",
          "pmid": "38787785"
        },
        {
          "paper_title": "Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover",
          "journal": "Molecular and Cellular Biology",
          "year": 2020,
          "relevant_quote": "Taken together, these data suggest a role for Cdc48/VCP-facilitated endocytosis in regulating TDP-43 and FUS turnover and thus toxicity. This suggests that endocytic dysfunction may represent a novel therapeutic target for numerous devastating neurodegenerative diseases characterized by TDP-43 and FUS cytoplasmic pathology.",
          "pmid": "31767634"
        }
      ],
      "pathway": {
        "name": "Aggrephagy",
        "canonical_name": "Aggrephagy",
        "ontology_id": "GO:0035973",
        "ontology_source": "GO",
        "confidence": 0.8
      },
      "pmids": [
        "38787785",
        "31767634"
      ],
      "interaction_effect": "activates",
      "interaction_direction": "main_to_primary",
      "function_effect": "activation"
    }
  ],
  "arrow": "binds",
  "direction": "main_to_primary",
  "intent": "regulation",
  "arrows": {
    "main_to_primary": [
      "activates"
    ]
  },
  "is_valid": true,
  "mechanism_correction": null,
  "mechanism": "VCP, a type II AAA+ ATPase, functions as a protein segregase that recognizes and extracts ubiquitinated TDP-43 from insoluble aggregates in both the nucleus and cytoplasm. This process is dependent on VCP's ATPase activity, which provides the energy to unfold and solubilize TDP-43, thereby facilitating its subsequent degradation through pathways like the proteasome or autophagy. This function is critical for maintaining protein homeostasis (proteostasis) and mitigating the neurotoxicity associated with TDP-43 proteinopathies.",
  "effect": "VCP directly facilitates the disassembly and clearance of toxic TDP-43 aggregates. Impairment of VCP function, through mutation or inhibition, leads to the accumulation of these aggregates, a key pathological hallmark in diseases like ALS and FTD.",
  "summary": "VCP activates TDP-43 to modulate tdp-43 aggregate clearance, ultimately affecting cellular proteotoxicity is reduced and neuronal function is preserved.",
  "evidence": [
    {
      "paper_title": "VCP activator reverses nuclear proteostasis defects and enhances TDP-43 aggregate clearance in multisystem proteinopathy models",
      "journal": "The Journal of Clinical Investigation",
      "year": 2024,
      "relevant_quote": "Consistent with a loss of nuclear VCP function, cells harboring MSP variants or cells treated with VCP inhibitor exhibited decreased clearance of insoluble intranuclear TDP-43 aggregates. Moreover, we identified 4 compounds that activate VCP primarily by increasing D2 ATPase activity, where pharmacologic VCP activation appears to enhance clearance of insoluble intranuclear TDP-43 aggregate."
    },
    {
      "paper_title": "Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover",
      "journal": "Molecular and Cellular Biology",
      "year": 2020,
      "relevant_quote": "Taken together, these data suggest a role for Cdc48/VCP-facilitated endocytosis in regulating TDP-43 and FUS turnover and thus toxicity. This suggests that endocytic dysfunction may represent a novel therapeutic target for numerous devastating neurodegenerative diseases characterized by TDP-43 and FUS cytoplasmic pathology."
    }
  ],
  "pathways": [
    {
      "name": "Aggrephagy",
      "canonical_name": "Aggrephagy",
      "ontology_id": "GO:0035973",
      "ontology_source": "GO",
      "confidence": 0.8
    }
  ],
  "interaction_effect": "binding",
  "_validation_metadata": {
    "validated": true,
    "validator": "arrow_effect_validator",
    "corrections_applied": 2
  },
  "_arrow_validated": true,
  "arrow_notation": "VCP --binds--> TDP-43:",
  "protein_a": "VCP",
  "protein_b": "TDP-43",
  "discovered_in_query": "VCP",
  "first_discovered": "2025-12-06T04:46:06.385142Z",
  "last_updated": "2025-12-06T04:46:06.385142Z"
}